Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

Exenatide (exendin‐4) exhibits dose‐dependent glucoregulatory activity, but causes dose‐limiting nausea and vomiting. This study was designed to formally assess the possibility of inducing tolerance to the side effects of nausea and vomiting at therapeutic doses of exenatide, using a dose‐escalation methodology.

[1]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[2]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[3]  A. Baron,et al.  Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. , 2003, Current opinion in investigational drugs.

[4]  J. Holst.  Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1 , 2002, Diabetes/metabolism research and reviews.

[5]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[6]  G. Mertes.  Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. , 2001, Diabetes research and clinical practice.

[7]  J. LeLorier,et al.  Predictors of persistence of use of the novel antidiabetic agent acarbose. , 2001, Archives of internal medicine.

[8]  R. DeFronzo.  Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[9]  J. Chan,et al.  An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With Diet , 1998, Diabetes Care.

[10]  N. Yorioka,et al.  Dose Escalation Induces Tolerance to Side-Effects of Erythropoietin in a Patient with Dialysis Anaemia: Case Report , 1998, The Journal of international medical research.

[11]  B. Göke,et al.  The evolving role of a-glucosidase inhibitors , 1998 .

[12]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[13]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[14]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .